Flash Finance

Blue Jet Healthcare LimitedBLUEJETCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹520.65
MCap ₹9,031 Cr · P/E 34.1
Blue Jet Healthcare Limited — Stock analysis & AI research Blue Jet Healthcare Limited — Multibagger AI analysis Blue Jet Healthcare Limited — Seasonality — best & worst months Blue Jet Healthcare Limited — Technical indicators & charts Blue Jet Healthcare Limited — Technical setup — score, trend, support & resistance Blue Jet Healthcare Limited — Falling Wedge pattern forming Blue Jet Healthcare Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹293 Cr
Sales · Jun 2026
-17.5% YoY
₹98 Cr
Operating Profit · Jun 2026
-19.0% YoY
33.4%
OPM % · Jun 2026
-2.1% YoY
₹78 Cr
Net Profit · Jun 2026
-14.3% YoY
₹4.51
EPS · Jun 2026
-14.3% YoY

📝 Blue Jet Healthcare Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Blue Jet Healthcare Limited reported revenue of ₹293 crore for the quarter ended June 2026 (Q1 FY27), down 17.5% from ₹355 crore in the same quarter last year, and up 24.7% sequentially over the March 2026 quarter.

Net profit fell 14.3% year-on-year to ₹78 crore, from ₹91 crore. Earnings per share (EPS) came in at ₹4.51.

Operating profit stood at ₹98 crore — an operating margin (OPM) of 33.4%, compared with 34.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Blue Jet Healthcare Limited posted revenue of ₹946 crore, a growth of 8.0% over FY25, with a net profit of ₹278 crore (up 0.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹884 crore with a net profit of ₹265 crore.

Valuation snapshot

At the current price of ₹520.65, BLUEJET has a market capitalisation of ₹9,031 crore and a trailing P/E of about 34.1.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 3rd-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 73.15%, foreign institutional investors (FIIs) 0.82%, domestic institutional investors (DIIs) 7.49%, public shareholders 18.55% of Blue Jet Healthcare Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹9,031 Cr
Current Price ?
₹520.6
P/E ?
34.10below ind
Industry P/E ?
37.20
P/B ?
6.64
P/S ?
10.22
P/FCF ?
78.53
Enterprise Value ?
₹9,073 Cr
EV/EBITDA ?
28.27
PEG ?
2.13
Earnings Yield ?
3.2%
Dividend Yield ?
0.23%
Profitability & Returns
Sales (TTM) ?
₹884 Cr
OPM ?
36.3%
Profit after tax (TTM) ?
₹265 Cr
EPS (TTM) ?
₹15.27
ROCE ?
26.0%
ROE ?
19.5%
ROA ?
16.1%
Growth
Sales — latest qtr ?
₹293 Cr
PAT — latest qtr ?
₹78 Cr
YoY qtr sales growth ?
-17.5%
YoY qtr profit growth ?
-14.3%
Sales growth (3y) ?
10%
Sales growth (5y) ?
14%
Profit growth (3y) ?
16%
Profit growth (5y) ?
12%
Financial Health
Debt ?
₹42 Cr
Debt to Equity ?
0.03
Interest Coverage ?
39.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
73.15%
Change in promoter holding ?
-12.85%
Pledged percentage ?
N/A
Market
Return 3 months ?
-10.9%
Return 6 months ?
23.2%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 217180181167184163208165340355165191235293 -17.5% +24.7%
Operating Profit 705963555344699214012155977198 -19.0% +38.0%
Other Income 65879912141282462315 +87.5% -34.8%
Interest 00000000015111 +0.0% +0.0%
Depreciation 666883512566767 +16.7% +16.7%
Profit Before Tax 7058644454497794147123699587106 -13.8% +21.8%
Net Profit 51444832403858701109152716478 -14.3% +21.9%
EPS 2.922.542.761.852.292.183.364.026.355.263.014.093.714.51 -14.3% +21.6%
OPM % 32.3% 32.8% 34.5% 32.7% 28.8% 27.0% 33.2% 55.7% 41.2% 34.1% 33.3% 50.7% 30.2% 33.4% -2.1% +10.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹876 Cr ₹946 Cr ₹884 Cr +8.0%
Operating Profit ₹345 Cr ₹344 Cr ₹321 Cr -0.2%
OPM % 39.36% 36.36% 36.30% -7.6%
NPM % 31.50% 29.37% 29.96% -6.8%
Other Income ₹47 Cr ₹61 Cr ₹68 Cr +29.7%
Depreciation ₹25 Cr ₹25 Cr ₹26 Cr +0.5%
Interest ₹0 Cr ₹8 Cr ₹8 Cr +4136.8%
EBIT ₹320 Cr ₹319 Cr ₹295 Cr -0.3%
PBT ₹367 Cr ₹374 Cr ₹357 Cr +2.0%
Tax ₹24 Cr ₹24 Cr ₹24 Cr +1.1%
Net Profit ₹276 Cr ₹278 Cr ₹265 Cr +0.7%
EPS ₹15.91 ₹16.07 ₹15.32 +1.0%
Material Cost ₹21 Cr ₹48 Cr ₹48 Cr +125.9%
Employee Cost ₹12 Cr ₹14 Cr ₹14 Cr +20.0%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 35353535 +0.0%
Reserves 6478111,0981,325 +20.7%
Borrowings 532142 +100.0%
Other Liabilities 176211263239 -9.1%
Total Liabilities 8621,0591,4181,641 +15.7%
Fixed Assets 151172300316 +5.3%
CWIP 3014789301 +238.2%
Investments 189250187252 +34.8%
Other Assets 491489841771 -8.3%
Total Assets 8621,0591,4181,641 +15.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 14224146334 +626.1%
Cash from Investing Activity -147-264-35-276 -688.6%
Cash from Financing Activity -4-2-19-31 -63.2%
Net Cash Flow -10-24-828 +450.0%
Free Cash Flow 8368-34115 +438.2%
CFO/OP 92%109%36%151% +319.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Days Payable 58357048 -31.4%
Debtor Days 12191124131 +5.6%
Inventory Days 137151209157 -24.9%
Cash Conversion Cycle 199206262240 -8.4%
Working Capital Days 12092157224 +42.7%
ROCE % 35%30%40%26% -35.0%

👥 Shareholding (latest 6 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026Sep 2026 % Chg
Promoters 79.81%79.81%79.81%79.81%73.15%73.15% +0.0%
FIIs 1.83%1.14%0.89%0.40%0.62%0.82% +32.3%
DIIs 3.63%4.65%4.51%4.65%9.12%7.49% -17.9%
Public 14.74%14.41%14.80%15.14%17.11%18.55% +8.4%
No. of Shareholders 80,11780,18779,19978,91778,92779,390 +0.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Blue Jet Healthcare Limited's revenue in Q1 FY27?
Blue Jet Healthcare Limited reported revenue of ₹293 crore for the quarter ended June 2026 (Q1 FY27), down 17.5% from ₹355 crore in the same quarter last year, and up 24.7% sequentially over the March 2026 quarter.
What was Blue Jet Healthcare Limited's net profit in Q1 FY27?
Net profit fell 14.3% year-on-year to ₹78 crore, from ₹91 crore. Earnings per share (EPS) came in at ₹4.51.
What is BLUEJET's market capitalisation and P/E ratio?
At the current price of ₹520.65, BLUEJET has a market capitalisation of ₹9,031 crore and a trailing P/E of about 34.1.
Who owns Blue Jet Healthcare Limited? (shareholding pattern)
As of Sep 2026, promoters held 73.15%, foreign institutional investors (FIIs) 0.82%, domestic institutional investors (DIIs) 7.49%, public shareholders 18.55% of Blue Jet Healthcare Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI